BioNTech company profile

BNTX · NASDAQ · USD

Compare BioNTech
$84.86Change from previous close: −0.47%Absolute change: −$0.40

Close · November 17, 2026

Company profile

BioNTech has 7,807 employees and is headquartered in Mainz, Germany.

The United States accounted for 62.5% of revenue in the fiscal year ended December 2025, ahead of Germany at 26.5% and Ireland at 10.6%. BioNTech SE, together with its subsidiaries, develops and commercializes immunotherapies, with its operations based in Germany. Its vaccine BNT162 is an mRNA product against SARS-CoV-2. The oncology pipeline includes drugs in Phase III trials, among them Gotistobart for metastatic non-small cell lung cancer and Pumitamig for small cell lung cancer, along with candidates for influenza, tuberculosis, malaria and mpox.

In the fiscal year ended December 2025, revenue reached EUR 2.9 billion, up 4.3% from the prior year, while the net loss came to EUR 1.1 billion. The company had 7,807 employees and is headquartered in Mainz, Germany, where it was incorporated in 2008.

Company facts

Industry
Biotechnology
Headquarters
An der Goldgrube 12, 55131, Mainz
Employees
7,807
Chief executive
Ugur Sahin
Founded
2008
Fiscal year
January - December
Listing
BNTX · NASDAQ
Currency
USD
ISIN
US09075V1026

BioNTech and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
BioNTechBNTXUnited States$21.22B7,807-55.4%—
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34
IncyteINCYUnited States$24.36B2,84432.2%61.0
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
InsmedINSMUnited States$26.96B1,664-41.7%—
ExelixisEXELUnited States$16.37B1,07740.2%20.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare BioNTech with its competitors